Condition
Follicular Lymphoma Grade 3B clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Follicular Lymphoma Grade 3B clinical trials that are recruiting, at sites in 3 countries (most in United States (2), China (2), Taiwan (1)). By phase: Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest Follicular Lymphoma Grade 3B clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma Sample Collection for MRD Testing | — | Austin, Texas | Recruiting | Aug 6, 2026 |
| C402 CD19 CAR treatment for relapsed or refractory large B‑cell lymphoma | Phase 1 | Tianjin | Recruiting | Feb 17, 2025 |
| Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310 | Phase 1 | Denver, Colorado and 4 other locations | Recruiting | Aug 9, 2024 |
| Long-term follow-up of gene-edited immune cell therapy for lymphoma | — | Kaohsiung, Taiwan and 4 other locations | Recruiting | May 17, 2022 |
| Treatment for newly diagnosed high tumor burden non-Hodgkin's lymphoma | — | Changchun, Jilin | Recruiting | Sep 10, 2021 |
All recruiting trials (5)
-
Non-Hodgkin Lymphoma Sample Collection for MRD Testing
This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.
-
C402 CD19 CAR treatment for relapsed or refractory large B‑cell lymphoma
We will try an autologous CD19-directed CAR‑T therapy (C402) in adults with relapsed or refractory CD19‑positive large B‑cell lymphoma to see if it is safe and tolerable.
-
Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310
This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.
-
Long-term follow-up of gene-edited immune cell therapy for lymphoma
This study is checking how safe and effective a gene-edited immune cell therapy is for people with lymphoma who received the treatment in the past.
-
Treatment for newly diagnosed high tumor burden non-Hodgkin's lymphoma
This study is testing a new treatment combination for people with newly diagnosed high tumor burden non-Hodgkin's lymphoma to see if it helps them feel better and stay safe.
Related topics
Quick answers
How many Follicular Lymphoma Grade 3B clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), China (2 trials), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.